TMO earnings track record
Beat analyst EPS estimates in 5 of the last 5 reported quarters, averaging a +2.85% surprise.
| Quarter | Reported | EPS est. | EPS actual | Surprise | Next session |
|---|---|---|---|---|---|
| Q2 2026 | —bmo | $5.77 | $6.03 | ▲ +4.54% | — |
| Q1 2026 | — | $5.29 | $5.44 | ▲ +2.84% | — |
| Q4 2025 | — | $6.51 | $6.57 | ▲ +0.91% | — |
| Q3 2025 | — | $5.55 | $5.79 | ▲ +4.37% | — |
| Q2 2025 | — | $5.28 | $5.36 | ▲ +1.61% | — |
Recent TMO events
- 2026-08-26NewsBenzingaDelta Air, Target, Thermo Fisher Scientific And A Financial Stock On CNBC’s ‘Final Trades’
- 2026-08-11NewsBenzingaWitnessing An Insider Decision, Joseph R Holmes Exercises Options Valued At $120K At Thermo Fisher Scientific
- 2026-08-11NewsYahooNon-Viral Transfection Reagents Market Report (3rd Edition) by Type of Non-Viral Transfection Method, Application Area, End-User & Region, Featuring Bio-Rad, MaxCyte, MilliporeSigma, Thermo Fisher Scientific
- 2026-08-10NewsYahooHow Investors Are Reacting To Thermo Fisher Scientific (TMO) New FDA-Cleared Multiple Myeloma Platform
- 2026-08-10NewsYahooThermo Fisher (TMO) vs Danaher (DHR): Which Life Sciences Stock Looks Better Positioned?
- 2026-07-31EarningsYahooAnalysts Appear Bullish on Thermo Fisher (TMO): Is The Stock Really a Buy After Earnings?
- 2026-07-30EarningsYahooThermo Fisher Scientific (TMO) Could Be 2% Undervalued After Q2 Earnings Beat
- 2026-07-27NewsYahooThermo Fisher Scientific Presents End-to-End Diagnostic and Lab Solutions Addressing Unmet Clinical Needs at ADLM 2026
- 2026-07-24EarningsYahooThermo Fisher Scientific's Strong Q2 Not Enough to 'Meaningfully' Change H2 Outlook, RBC Says
- 2026-07-24EarningsYahooTMO Q2 Deep Dive: Broad-Based End Market Growth and Strategic Portfolio Moves
Important Disclaimer — Not Investment Advice
Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.
Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.
- You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
- Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
- Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
- We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
- Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
- Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.
Full terms: Disclaimer · Terms of Service · Privacy Policy